Stock Analysis on Net
Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

デュポンの分析: ROE、ROA、純利益率の内訳 
四半期データ

Microsoft Excel

ROE分解では、純利益を株主資本で割ったものを構成比率の積として表します。

ROEを2つのコンポーネントに分解

Regeneron Pharmaceuticals Inc.、 ROE の分解(四半期データ)

Microsoft Excel
ROE = ROA × 財務レバレッジ比率
2025/03/31 15.31% = 11.98% × 1.28
2024/12/31 15.03% = 11.69% × 1.29
2024/09/30 15.87% = 12.43% × 1.28
2024/06/30 15.32% = 11.98% × 1.28
2024/03/31 14.29% = 11.22% × 1.27
2023/12/31 15.22% = 11.95% × 1.27
2023/09/30 16.03% = 12.41% × 1.29
2023/06/30 17.90% = 14.02% × 1.28
2023/03/31 17.80% = 13.91% × 1.28
2022/12/31 19.14% = 14.85% × 1.29
2022/09/30 25.05% = 19.40% × 1.29
2022/06/30 27.49% = 20.90% × 1.32
2022/03/31 39.84% = 30.11% × 1.32
2021/12/31 43.03% = 31.75% × 1.36
2021/09/30 40.53% = 29.55% × 1.37
2021/06/30 41.02% = 28.88% × 1.42
2021/03/31 33.43% = 22.53% × 1.48
2020/12/31 31.86% = 20.47% × 1.56
2020/09/30 — = — × 1.59
2020/06/30 — = — × 1.59
2020/03/31 — = — × 1.30

レポートに基づく: 10-Q (報告日: 2025-03-31), 10-K (報告日: 2024-12-31), 10-Q (報告日: 2024-09-30), 10-Q (報告日: 2024-06-30), 10-Q (報告日: 2024-03-31), 10-K (報告日: 2023-12-31), 10-Q (報告日: 2023-09-30), 10-Q (報告日: 2023-06-30), 10-Q (報告日: 2023-03-31), 10-K (報告日: 2022-12-31), 10-Q (報告日: 2022-09-30), 10-Q (報告日: 2022-06-30), 10-Q (報告日: 2022-03-31), 10-K (報告日: 2021-12-31), 10-Q (報告日: 2021-09-30), 10-Q (報告日: 2021-06-30), 10-Q (報告日: 2021-03-31), 10-K (報告日: 2020-12-31), 10-Q (報告日: 2020-09-30), 10-Q (報告日: 2020-06-30), 10-Q (報告日: 2020-03-31).

2025年第1 四半期の株主資本利益率(ROE)が上昇した主な理由は、総資産利益率(ROA)で測定される収益性の向上です。

ROEを3つの要素に分解

Regeneron Pharmaceuticals Inc.、 ROE の分解(四半期データ)

Microsoft Excel
ROE = 純利益率 × 資産回転率 × 財務レバレッジ比率
2025/03/31 15.31% = 31.94% × 0.38 × 1.28
2024/12/31 15.03% = 31.07% × 0.38 × 1.29
2024/09/30 15.87% = 33.61% × 0.37 × 1.28
2024/06/30 15.32% = 32.04% × 0.37 × 1.28
2024/03/31 14.29% = 29.45% × 0.38 × 1.27
2023/12/31 15.22% = 30.14% × 0.40 × 1.27
2023/09/30 16.03% = 30.47% × 0.41 × 1.29
2023/06/30 17.90% = 33.93% × 0.41 × 1.28
2023/03/31 17.80% = 33.81% × 0.41 × 1.28
2022/12/31 19.14% = 35.64% × 0.42 × 1.29
2022/09/30 25.05% = 39.17% × 0.50 × 1.29
2022/06/30 27.49% = 39.97% × 0.52 × 1.32
2022/03/31 39.84% = 48.06% × 0.63 × 1.32
2021/12/31 43.03% = 50.25% × 0.63 × 1.36
2021/09/30 40.53% = 51.65% × 0.57 × 1.37
2021/06/30 41.02% = 50.11% × 0.58 × 1.42
2021/03/31 33.43% = 43.53% × 0.52 × 1.48
2020/12/31 31.86% = 41.35% × 0.50 × 1.56
2020/09/30 — = — × — × 1.59
2020/06/30 — = — × — × 1.59
2020/03/31 — = — × — × 1.30

レポートに基づく: 10-Q (報告日: 2025-03-31), 10-K (報告日: 2024-12-31), 10-Q (報告日: 2024-09-30), 10-Q (報告日: 2024-06-30), 10-Q (報告日: 2024-03-31), 10-K (報告日: 2023-12-31), 10-Q (報告日: 2023-09-30), 10-Q (報告日: 2023-06-30), 10-Q (報告日: 2023-03-31), 10-K (報告日: 2022-12-31), 10-Q (報告日: 2022-09-30), 10-Q (報告日: 2022-06-30), 10-Q (報告日: 2022-03-31), 10-K (報告日: 2021-12-31), 10-Q (報告日: 2021-09-30), 10-Q (報告日: 2021-06-30), 10-Q (報告日: 2021-03-31), 10-K (報告日: 2020-12-31), 10-Q (報告日: 2020-09-30), 10-Q (報告日: 2020-06-30), 10-Q (報告日: 2020-03-31).

2025年第1 四半期の株主資本利益率(ROE)が上昇した主な理由は、純利益率で測定される収益性の向上です。

ROEを5つの要素に分解

Regeneron Pharmaceuticals Inc.、 ROE の分解(四半期データ)

Microsoft Excel
ROE = 税負担 × 利息負担 × EBITマージン × 資産回転率 × 財務レバレッジ比率
2025/03/31 15.31% = 0.90 × 0.99 × 35.72% × 0.38 × 1.28
2024/12/31 15.03% = 0.92 × 0.99 × 34.05% × 0.38 × 1.29
2024/09/30 15.87% = 0.94 × 0.99 × 36.34% × 0.37 × 1.28
2024/06/30 15.32% = 0.94 × 0.99 × 34.50% × 0.37 × 1.28
2024/03/31 14.29% = 0.95 × 0.98 × 31.40% × 0.38 × 1.27
2023/12/31 15.22% = 0.94 × 0.98 × 32.57% × 0.40 × 1.27
2023/09/30 16.03% = 0.91 × 0.98 × 33.97% × 0.41 × 1.29
2023/06/30 17.90% = 0.90 × 0.99 × 38.24% × 0.41 × 1.28
2023/03/31 17.80% = 0.90 × 0.99 × 38.15% × 0.41 × 1.28
2022/12/31 19.14% = 0.89 × 0.99 × 40.40% × 0.42 × 1.29
2022/09/30 25.05% = 0.89 × 0.99 × 44.45% × 0.50 × 1.29
2022/06/30 27.49% = 0.90 × 0.99 × 44.98% × 0.52 × 1.32
2022/03/31 39.84% = 0.87 × 0.99 × 55.67% × 0.63 × 1.32
2021/12/31 43.03% = 0.87 × 0.99 × 58.38% × 0.63 × 1.36
2021/09/30 40.53% = 0.87 × 0.99 × 59.85% × 0.57 × 1.37
2021/06/30 41.02% = 0.86 × 0.99 × 58.94% × 0.58 × 1.42
2021/03/31 33.43% = 0.91 × 0.99 × 48.49% × 0.52 × 1.48
2020/12/31 31.86% = 0.92 × 0.99 × 45.51% × 0.50 × 1.56
2020/09/30 — = — × — × — × — × 1.59
2020/06/30 — = — × — × — × — × 1.59
2020/03/31 — = — × — × — × — × 1.30

レポートに基づく: 10-Q (報告日: 2025-03-31), 10-K (報告日: 2024-12-31), 10-Q (報告日: 2024-09-30), 10-Q (報告日: 2024-06-30), 10-Q (報告日: 2024-03-31), 10-K (報告日: 2023-12-31), 10-Q (報告日: 2023-09-30), 10-Q (報告日: 2023-06-30), 10-Q (報告日: 2023-03-31), 10-K (報告日: 2022-12-31), 10-Q (報告日: 2022-09-30), 10-Q (報告日: 2022-06-30), 10-Q (報告日: 2022-03-31), 10-K (報告日: 2021-12-31), 10-Q (報告日: 2021-09-30), 10-Q (報告日: 2021-06-30), 10-Q (報告日: 2021-03-31), 10-K (報告日: 2020-12-31), 10-Q (報告日: 2020-09-30), 10-Q (報告日: 2020-06-30), 10-Q (報告日: 2020-03-31).

2025年第1 四半期の株主資本利益率(ROE)が上昇した主な理由は、EBITマージン率で測定される営業利益率の増加です。

ROAを2つのコンポーネントに分解

Regeneron Pharmaceuticals Inc.、 ROA の分解(四半期データ)

Microsoft Excel
ROA = 純利益率 × 資産回転率
2025/03/31 11.98% = 31.94% × 0.38
2024/12/31 11.69% = 31.07% × 0.38
2024/09/30 12.43% = 33.61% × 0.37
2024/06/30 11.98% = 32.04% × 0.37
2024/03/31 11.22% = 29.45% × 0.38
2023/12/31 11.95% = 30.14% × 0.40
2023/09/30 12.41% = 30.47% × 0.41
2023/06/30 14.02% = 33.93% × 0.41
2023/03/31 13.91% = 33.81% × 0.41
2022/12/31 14.85% = 35.64% × 0.42
2022/09/30 19.40% = 39.17% × 0.50
2022/06/30 20.90% = 39.97% × 0.52
2022/03/31 30.11% = 48.06% × 0.63
2021/12/31 31.75% = 50.25% × 0.63
2021/09/30 29.55% = 51.65% × 0.57
2021/06/30 28.88% = 50.11% × 0.58
2021/03/31 22.53% = 43.53% × 0.52
2020/12/31 20.47% = 41.35% × 0.50
2020/09/30 — = — × —
2020/06/30 — = — × —
2020/03/31 — = — × —

レポートに基づく: 10-Q (報告日: 2025-03-31), 10-K (報告日: 2024-12-31), 10-Q (報告日: 2024-09-30), 10-Q (報告日: 2024-06-30), 10-Q (報告日: 2024-03-31), 10-K (報告日: 2023-12-31), 10-Q (報告日: 2023-09-30), 10-Q (報告日: 2023-06-30), 10-Q (報告日: 2023-03-31), 10-K (報告日: 2022-12-31), 10-Q (報告日: 2022-09-30), 10-Q (報告日: 2022-06-30), 10-Q (報告日: 2022-03-31), 10-K (報告日: 2021-12-31), 10-Q (報告日: 2021-09-30), 10-Q (報告日: 2021-06-30), 10-Q (報告日: 2021-03-31), 10-K (報告日: 2020-12-31), 10-Q (報告日: 2020-09-30), 10-Q (報告日: 2020-06-30), 10-Q (報告日: 2020-03-31).

2025年第1 四半期の総資産利益率(ROA)が上昇した主な理由は、純利益率で測定した収益性の向上です。

ROAを4つの要素に分解

Regeneron Pharmaceuticals Inc.、 ROA の分解(四半期データ)

Microsoft Excel
ROA = 税負担 × 利息負担 × EBITマージン × 資産回転率
2025/03/31 11.98% = 0.90 × 0.99 × 35.72% × 0.38
2024/12/31 11.69% = 0.92 × 0.99 × 34.05% × 0.38
2024/09/30 12.43% = 0.94 × 0.99 × 36.34% × 0.37
2024/06/30 11.98% = 0.94 × 0.99 × 34.50% × 0.37
2024/03/31 11.22% = 0.95 × 0.98 × 31.40% × 0.38
2023/12/31 11.95% = 0.94 × 0.98 × 32.57% × 0.40
2023/09/30 12.41% = 0.91 × 0.98 × 33.97% × 0.41
2023/06/30 14.02% = 0.90 × 0.99 × 38.24% × 0.41
2023/03/31 13.91% = 0.90 × 0.99 × 38.15% × 0.41
2022/12/31 14.85% = 0.89 × 0.99 × 40.40% × 0.42
2022/09/30 19.40% = 0.89 × 0.99 × 44.45% × 0.50
2022/06/30 20.90% = 0.90 × 0.99 × 44.98% × 0.52
2022/03/31 30.11% = 0.87 × 0.99 × 55.67% × 0.63
2021/12/31 31.75% = 0.87 × 0.99 × 58.38% × 0.63
2021/09/30 29.55% = 0.87 × 0.99 × 59.85% × 0.57
2021/06/30 28.88% = 0.86 × 0.99 × 58.94% × 0.58
2021/03/31 22.53% = 0.91 × 0.99 × 48.49% × 0.52
2020/12/31 20.47% = 0.92 × 0.99 × 45.51% × 0.50
2020/09/30 — = — × — × — × —
2020/06/30 — = — × — × — × —
2020/03/31 — = — × — × — × —

レポートに基づく: 10-Q (報告日: 2025-03-31), 10-K (報告日: 2024-12-31), 10-Q (報告日: 2024-09-30), 10-Q (報告日: 2024-06-30), 10-Q (報告日: 2024-03-31), 10-K (報告日: 2023-12-31), 10-Q (報告日: 2023-09-30), 10-Q (報告日: 2023-06-30), 10-Q (報告日: 2023-03-31), 10-K (報告日: 2022-12-31), 10-Q (報告日: 2022-09-30), 10-Q (報告日: 2022-06-30), 10-Q (報告日: 2022-03-31), 10-K (報告日: 2021-12-31), 10-Q (報告日: 2021-09-30), 10-Q (報告日: 2021-06-30), 10-Q (報告日: 2021-03-31), 10-K (報告日: 2020-12-31), 10-Q (報告日: 2020-09-30), 10-Q (報告日: 2020-06-30), 10-Q (報告日: 2020-03-31).

2025年第1 四半期の総資産利益率(ROA)が上昇した主な理由は、EBITマージン率で測定した営業利益率の増加です。

当期純利益率の分解

Regeneron Pharmaceuticals Inc.、純利益率の分解(四半期データ)

Microsoft Excel
純利益率 = 税負担 × 利息負担 × EBITマージン
2025/03/31 31.94% = 0.90 × 0.99 × 35.72%
2024/12/31 31.07% = 0.92 × 0.99 × 34.05%
2024/09/30 33.61% = 0.94 × 0.99 × 36.34%
2024/06/30 32.04% = 0.94 × 0.99 × 34.50%
2024/03/31 29.45% = 0.95 × 0.98 × 31.40%
2023/12/31 30.14% = 0.94 × 0.98 × 32.57%
2023/09/30 30.47% = 0.91 × 0.98 × 33.97%
2023/06/30 33.93% = 0.90 × 0.99 × 38.24%
2023/03/31 33.81% = 0.90 × 0.99 × 38.15%
2022/12/31 35.64% = 0.89 × 0.99 × 40.40%
2022/09/30 39.17% = 0.89 × 0.99 × 44.45%
2022/06/30 39.97% = 0.90 × 0.99 × 44.98%
2022/03/31 48.06% = 0.87 × 0.99 × 55.67%
2021/12/31 50.25% = 0.87 × 0.99 × 58.38%
2021/09/30 51.65% = 0.87 × 0.99 × 59.85%
2021/06/30 50.11% = 0.86 × 0.99 × 58.94%
2021/03/31 43.53% = 0.91 × 0.99 × 48.49%
2020/12/31 41.35% = 0.92 × 0.99 × 45.51%
2020/09/30 — = — × — × —
2020/06/30 — = — × — × —
2020/03/31 — = — × — × —

レポートに基づく: 10-Q (報告日: 2025-03-31), 10-K (報告日: 2024-12-31), 10-Q (報告日: 2024-09-30), 10-Q (報告日: 2024-06-30), 10-Q (報告日: 2024-03-31), 10-K (報告日: 2023-12-31), 10-Q (報告日: 2023-09-30), 10-Q (報告日: 2023-06-30), 10-Q (報告日: 2023-03-31), 10-K (報告日: 2022-12-31), 10-Q (報告日: 2022-09-30), 10-Q (報告日: 2022-06-30), 10-Q (報告日: 2022-03-31), 10-K (報告日: 2021-12-31), 10-Q (報告日: 2021-09-30), 10-Q (報告日: 2021-06-30), 10-Q (報告日: 2021-03-31), 10-K (報告日: 2020-12-31), 10-Q (報告日: 2020-09-30), 10-Q (報告日: 2020-06-30), 10-Q (報告日: 2020-03-31).

2025年第1 四半期の純利益率の上昇の主な理由は、EBITマージン率で測定される営業利益率の増加です。